Ascendis TransCon IL-2 β⁄γ Monotherapy, Combo Therapy Data Confirm Clinical Activity Across Tumor Types

 Clinical responses with TransCon IL-2 β⁄γ demonstrated as monotherapy or in combination with checkpoint inhibitor, including in two of three small cell lung cancer patients treated with combination therapy

— TransCon IL-2 β⁄γ administered every three weeks was generally well tolerated as a monotherapy or in combination with pembrolizumab, with no meaningful effect on T_regs and eosinophils

— Enrollment continues in indication-specific cohorts for Phase 2 portion of the IL-Believe Trial

https://www.biospace.com/article/releases/ascendis-presents-updated-and-new-transcon-il-2-%ce%b2-%ce%b3-monotherapy-and-combination-therapy-data-confirming-clinical-activity-across-tumor-types-at-esmo-2023/